PlushCare vs Wisp
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
PlushCare
Best for readers who want a primary-care relationship with GLP-1 prescribing as one option, AND who read the class-action disclosure and verify the cancellation flow before subscribingStarting at $149/mo
Wisp
Best for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-testedStarting at $225/mo
Side-by-Side Comparison
| Feature | PlushCare | Wisp |
|---|---|---|
| Overall Score | 7.0/10 | 7.0/10 |
| Starting Price | ✓$149/mo | $225/mo |
| Editorial Rating | 3.5 ★ /5 | 3.5 ★ /5 |
| Features | ✓7 features | 6 features |
| States Available | ✓50 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
PlushCare
Pros
- ✓All 50 states per the homepage
- ✓Appointments with US board-certified physicians (not nurse practitioners only)
- ✓Operates as virtual primary care, so the same provider can write GLP-1 prescriptions alongside other primary-care needs
- ✓Owned by Transcarent (post-Accolade-acquisition), a venture-backed health platform with named corporate parent
Cons
- ✗ACTIVE LITIGATION: California class action alleging deceptive subscription enrollment and unauthorized post-cancellation charges on the $19.99/month membership. Material disclosure for any reader signing up.
- ✗GLP-1 prescribing is clinician-discretionary at the visit level — not a guaranteed offering at intake
- ✗BBB rating reflects an ongoing pattern of complaints around the membership cancellation flow
Wisp
Pros
- ✓Wider GLP-1 menu than the prior stub suggested — both branded injectables (Wegovy, Zepbound, Saxenda) AND the compounded sublingual option
- ✓LegitScript certified, board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC publicly named)
- ✓Wisp's product page uses appropriately cautious language around sublingual: 'lab tests using human-derived tissues suggest it may begin working' and 'effectiveness in patients may vary' — disclosure is more rigorous than most compounded GLP-1 marketing
Cons
- ✗EFFECTIVENESS CAVEAT: sublingual compounded semaglutide has not been tested in humans — Wisp's own product page explicitly states this. Injectables (Wegovy, Zepbound, Saxenda) on the same platform have FDA safety/efficacy data; sublingual does not.
- ✗Pharmacy partners not publicly named
- ✗States served list not publicly enumerated
Our Verdict
Both PlushCare and Wisp score equally well overall — the right choice depends on your priorities. Choose PlushCare if you want readers who want a primary-care relationship with GLP-1 prescribing as one option, AND who read the class-action disclosure and verify the cancellation flow before subscribing, or Wisp if buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested matters most to you.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.